Anti-amyloid precursor protein immunoglobulins inhibit amyloid-β production by steric hindrance

FEBS Journal

Volumn 278, Issue 1, 2011, Pages 167-178

  Thomas, Rhian S ^a   Liddell, J Eryl ^a   Kidd, Emma J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

secretase cleavage site; Alzheimer's disease; amyloid precursor protein; amyloid ; monoclonal antibodies

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BETA SECRETASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B12; MONOCLONAL ANTIBODY 2B3; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; ASTROCYTOMA CELL; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL FREE SYSTEM; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG PROTEIN BINDING; ENZYME INHIBITION; INCUBATION TIME; INTRACELLULAR TRANSPORT; PH; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN SYNTHESIS INHIBITION; STEREOSPECIFICITY;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANTIBODIES, MONOCLONAL; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULINS;

EID: 78650497411     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07942.x     Document Type: Article

References (43)

1. Selkoe DJ, (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
2. Hardy J, &, Allsop D, (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
3. Bennett DA, Schneider JA, Wilson RS, Bienias JL, &, Arnold SE, (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61, 378-384.
4. Hamaguchi T, Ono K, &, Yamada M, (2006) Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 63, 1538-1552.
5. Mori H, Takio K, Ogawara M, &, Selkoe DJ, (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267, 17082-17086.
6. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, &, Ishiura S, (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 301, 231-235.
7. Allinson TM, Parkin ET, Turner AJ, &, Hooper NM, (2003) ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 74, 342-352.
8. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540.
9. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
10. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537.
11. Citron M, (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5, 677-685.
12. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, &, Haass C, (2003) Reconstitution of gamma-secretase activity. Nat Cell Biol 5, 486-488.
13. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, &, Selkoe DJ, (2003) Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 100, 6382-6387.
14. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, &, Iwatsubo T, (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422, 438-441.
15. Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, Gu Y, Sanjo N, Glista M, Rogaeva E, et al. (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440, 1208-1212.
16. Yamazaki T, Koo EH, &, Selkoe DJ, (1996) Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J Cell Sci 109, 999-1008.
17. Koo EH, Squazzo SL, Selkoe DJ, &, Koo CH, (1996) Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci 109, 991-998.
18. Accessed 1 July 2010.
19. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang JP, Johnson-Wood K, Khan K, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
20. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, et al. (2005) Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 25, 9096-9101.
21. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919.
22. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
23. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
24. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, &, Klein WL, (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79, 595-605.
25. Schenk D, (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3, 824-828.
26. Thomas RS, Liddell JE, Murphy LS, Pache DM, &, Kidd EJ, (2006) An antibody to the beta-secretase cleavage site on amyloid-beta-protein precursor inhibits amyloid-beta production. J Alzheimers Dis 10, 379-390.
27. Chong YH, Jung JM, Choi W, Park CW, Choi KS, &, Suh YH, (1994) Bacterial expression, purification of full length and carboxyl terminal fragment of Alzheimer amyloid precursor protein and their proteolytic processing by thrombin. Life Sci 54, 1259-1268.
28. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, &, Gouras GK, (2007) Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 282, 18895-18906.
29. Geisow MJ, &, Evans WH, (1984) pH in the endosome. Measurements during pinocytosis and receptor-mediated endocytosis. Exp Cell Res 150, 36-46.
30. Murphy RF, Powers S, &, Cantor CR, (1984) Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6. J Cell Biol 98, 1757-1762.
31. Dejaegere A, Choulier L, Lafont V, De Genst E, &, Altschuh D, (2005) Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study. Biochemistry 44, 14409-14418.
32. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, &, Selkoe DJ, (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1, 1291-1296.
33. Weiner HL, &, Frenkel D, (2006) Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6, 404-416.
34. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, &, Morgan D, (2003) Intracranially administered anti-A beta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23, 3745-3751.
35. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, et al. (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24, 6144-6151.
36. Arbel M, Yacoby I, &, Solomon B, (2005) Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci USA 102, 7718-7723.
37. Rakover I, Arbel M, &, Solomon B, (2007) Immunotherapy against APP β-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Aβ levels. Neurodegener Dis 4, 392-402.
38. Solomon B, &, Frenkel D, (2010) Immunotherapy for Alzheimer's disease. Neuropharmacology 59, 303-309.
39. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223.
40. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, &, Weller RO, (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9, 448-452.
41. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, &, Costa-Jussa F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14, 11-20.
42. McGeer PL, (2008) Amyloid-beta vaccination for Alzheimer's dementia. Lancet 372, 1381-1382.
43. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.